BETA: Please send your feedback!
Spectrum Pharmaceuticals
SPPI:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2021
—
About
Biotechnology
Founded 1987
Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It targets non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma. It operates through the following brands: FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, EVOMELA, EOQUIN, and RenaZorb. The company was founded in December 1987 and is headquartered in Henderson, NV.
website
Headquarters
Executives
| Name | Title | Gender |
| Rajesh C. Shrotriya, MD | Chairman & Chief Executive Officer | Male |
| Shiv S. Kapoor, MBA | VP-Strategic Planning & Investor Relations | Male |
| Joseph W. Turgeon, MBA | President & Chief Operating Officer | Male |
| Kurt A. Gustafson, MBA | Chief Financial Officer & Executive Vice President | Male |
| Abraham Noah Oler, CFA | Chief of Staff & Vice President-Operations | Male |
Mindful Investing Summary
Spectrum Pharmaceuticals - Competitors and Related Companies
How Spectrum Pharmaceuticals stacks up to its peers in the Biotechnology industry or with competing business segments.
Spectrum Pharmaceuticals
SPPI:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2021
—
Seattle Genetics
SGEN:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2021
—
Mylan
MYL:NAS
Pharmaceuticals: Generic
—
LARGE cap
(—)
—
since start of 2021
—
Teva Pharmaceutical Industries
TEVA-IL:TAE
Pharmaceuticals: Generic
—
LARGE cap
(—)
—
since start of 2021
—
Biogen
BIIB:NAS
Biotechnology
—
MEGA cap
(—)
—
since start of 2021
—
Pfizer
PFE:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2021
—